PAR2-mediated epigenetic upregulation of α-synuclein contributes to the pathogenesis of Parkinsons disease

Brain Research

Volumn 1565, Issue , 2014, Pages 82-89

  Liu, Ping ^a   Sun, Liang ^a   Zhao, Xu Li ^a   Zhang, Peng ^a   Zhao, Xue Mei ^a   Zhang, Jian ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Histone acetylation; Nuclear factor B; Parkinsons disease; Proteinase activated receptor 2; synuclein

Indexed keywords

ALPHA SYNUCLEIN; HISTONE H3; INTERLEUKIN 1BETA; PROTEINASE ACTIVATED RECEPTOR 2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTONE ACETYLATION; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION; ANIMAL; DISEASE MODEL; GENETIC EPIGENESIS; GENETICS; METABOLISM; MPTP POISONING; PHOSPHORYLATION; WISTAR RAT;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; MALE; MPTP POISONING; NF-KAPPA B; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTOR, PAR-2; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 84899956159     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.04.014     Document Type: Article

References (32)

1. A. Afkhami-Goli, F. Noorbakhsh, A.J. Keller, N. Vergnolle, D. Westaway, J.H. Jhamandas, P. Andrade-Gordon, M.D. Hollenberg, H. Arab, R.H. Dyck, and C. Power Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimers disease J. Immunol. 179 2007 5493 5503
2. V. Bagetta, V. Ghiglieri, C. Sgobio, P. Calabresi, and B. Picconi Synaptic dysfunction in Parkinsons disease Biochem. Soc. Trans. 38 2010 493 497
3. W. Dauer, and S. Przedborski Parkinsons disease: mechanisms and models Neuron 39 2003 889 909
4. O.M. El-Agnaf, S.A. Salem, K.E. Paleologou, M.D. Curran, M.J. Gibson, J.A. Court, M.G. Schlossmacher, and D. Allsop Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinsons disease FASEB J. 20 2006 419 425
5. N. Federman, V. de la Fuente, G. Zalcman, N. Corbi, A. Onori, C. Passananti, and A. Romano Nuclear factor kappaB-dependent histone acetylation is specifically involved in persistent forms of memory J. Neurosci. 33 2013 7603 7614
6. M. Goedert, and M.G. Spillantini Lewy body diseases and multiple system atrophy as alpha-synucleinopathies Mol. Psychiatry 3 1998 462 465
7. M. Goedert Alpha-synuclein and neurodegenerative diseases Nat. Rev. Neurosci. 2 2001 492 501
8. M.D. Hollenberg, K. Mihara, D. Polley, J.Y. Suen, A. Han, D.P. Fairlie, and R. Ramachandran Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease Br. J. Pharmacol 171 2014 1180 1194
9. C. Kim, D.H. Ho, J.E. Suk, S. You, S. Michael, J. Kang, S. Joong Lee, E. Masliah, D. Hwang, H.J. Lee, and S.J. Lee Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia Nat. Commun. 4 2013 1562
10. H.J. Lee, E.J. Bae, and S.J. Lee Extracellular alpha-synuclein-a novel and crucial factor in Lewy body diseases Nat. Rev. Neurol. 10 2014 92 98
11. A. Lessard, and R. Couture Modulation of cardiac activity by tachykinins in the rat substantia nigra Br. J. Pharmacol. 134 2001 1749 1759
12. K.C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'Brien, J.Q. Trojanowski, and V.M. Lee Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice Science 338 2012 949 953
13. G.F. Ma, S. Chen, L. Yin, X.D. Gao, and W.B. Yao Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-kappaB pathway Acta Pharmacol. Sin. 35 2014 195 202
14. M.R. Marques, F. Stigger, E. Segabinazi, O.A. Augustin, S. Barbosa, F.V. Piazza, M. Achaval, and S. Marcuzzo Beneficial effects of early environmental enrichment on motor development and spinal cord plasticity in a rat model of cerebral palsy Behav. Brain Res. 263 2014 149 157
15. J. Massano, and K.P. Bhatia Clinical approach to Parkinsons disease: features, diagnosis, and principles of management Cold Spring Harb. Perspect. Med. 2 2012 a008870
16. I. Maze, K.M. Noh, and C.D. Allis Histone regulation in the CNS: basic principles of epigenetic plasticity Neuropsychopharmacology 38 2013 3 22
17. T. Mori, T. Hayashi, and T.P. Su Compromising sigma-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-kappaB/Bcl-2-dependent mechanism: potential relevance to Parkinsons disease J. Pharmacol. Exp. Ther. 341 2012 663 671
18. F. Noorbakhsh, S. Tsutsui, N. Vergnolle, L.A. Boven, N. Shariat, M. Vodjgani, K.G. Warren, P. Andrade-Gordon, M.D. Hollenberg, and C. Power Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis J. Exp. Med. 203 2006 425 435
19. E.H. Norris, B.I. Giasson, and V.M. Lee Alpha-synuclein: normal function and role in neurodegenerative diseases Curr. Top. Dev. Biol. 60 2004 17 54
20. C. Peng, L. Aron, R. Klein, M. Li, W. Wurst, N. Prakash, and W. Le Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons J. Neurosci. 31 2011 12802 12815
21. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W.G. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe, and R.L. Nussbaum Mutation in the alpha-synuclein gene identified in families with Parkinsons disease Science 276 1997 2045 2047
22. E. Pranski, C.D. Van Sanford, N. Dalal, A.L. Orr, D. Karmali, D.S. Cooper, M. Gearing, J.J. Lah, A.I. Levey, and R. Betarbet NF-kappaB activity is inversely correlated to RNF11 expression in Parkinsons disease Neurosci. Lett. 547 2013 16 20
23. A.D. Reynolds, J.G. Glanzer, I. Kadiu, M. Ricardo-Dukelow, A. Chaudhuri, P. Ciborowski, R. Cerny, B. Gelman, M.P. Thomas, R.L. Mosley, and H.E. Gendelman Nitrated alpha-synuclein-activated microglial profiling for Parkinsons disease J. Neurochem. 104 2008 1504 1525
24. J. Rizo, and T.C. Sudhof The membrane fusion enigma: SNAREs, Sec1/Munc18 proteins, and their accomplices - guilty as charged? Annu. Rev. Cell Dev. Biol. 28 2012 279 308
25. A.S. Rothmeier, and W. Ruf Protease-activated receptor 2 signaling in inflammation Semin. Immunopathol. 34 2012 133 149
26. A. Roy, A. Ghosh, A. Jana, X. Liu, S. Brahmachari, H.E. Gendelman, and K. Pahan Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinsons disease PLoS One 7 2012 e38113
27. A. Rudenko, and L.H. Tsai Epigenetic modifications in the nervous system and their impact upon cognitive impairments Neuropharmacology 80C 2014 70 82
28. E. Saracchi, S. Fermi, and L. Brighina Emerging candidate biomarkers for Parkinsons disease: a review Aging Dis. 5 2014 27 34
29. K.J. Spinelli, J.K. Taylor, V.R. Osterberg, M.J. Churchill, E. Pollock, C. Moore, C.K. Meshul, and V.K. Unni Presynaptic alpha-synuclein aggregation in a mouse model of Parkinsons disease J. Neurosci. 34 2014 2037 2050
30. W. Sriwai, S. Mahavadi, O. Al-Shboul, J.R. Grider, and K.S. Murthy Distinctive G protein-dependent signaling by protease-activated receptor 2 (PAR2) in smooth muscle: feedback inhibition of RhoA by cAMP-independent PKA PLoS One 8 2013 e66743
31. C.A. Williams, Y. Lin, A. Maynard, and S.Y. Cheng Involvement of NF Kappa B in potentiated effect of Mn-containing dithiocarbamates on MPP(+) induced cell death Cell Mol. Neurobiol. 33 2013 815 823
32. Y. Yabuki, Y. Ohizumi, A. Yokosuka, Y. Mimaki, and K. Fukunaga Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice Neuroscience 2013